CompaniesHealthcare & FitnessPharmaceuticalsPrint articleBrief: Antisense TherapeuticsCorporate news snapshot for Antisense TherapeuticsNov 24, 2009 – 2.24pmSaveLog in or Subscribe to save articleShareCopy linkCopiedEmailLinkedInTwitterFacebookCopy linkCopiedShare via...Gift this articleSubscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber? Login Antisense Therapeutics has received a patent allowance from the US Patent Office for application 10/789,526, entitled “Modulation of Growth Hormone Receptor Expression and Insulin like Growth Factor Expression", which covers the ATL1103 compound. Loading...SaveLog in or Subscribe to save articleShareCopy linkCopiedEmailLinkedInTwitterFacebookCopy linkCopiedShare via...Gift this articleSubscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber? LoginLicense articleIntroducing your NewsfeedFollow the topics, people and companies that matter to you.Find out moreRead MorePharmaceuticalsAntisense TherapeuticsLatest In Healthcare & fitnessFetching latest articlesMost Viewed In Companies
